| abstract |
The present invention relates to a pharmaceutical composition for preventing or treating fracture or osteoporosis, which contains, as an active ingredient, a gene selected from the group consisting of slit1, slit2, slit3, robo1, robo2, and virus, or an expressed protein thereof. A marker composition for predicting the risk of occurrence of fractures or osteoporosis, a kit for predicting the risk of occurrence of fractures or osteoporosis including an antibody that specifically binds to the protein, and an antigen using an antibody that specifically binds to the protein- The present invention relates to a method for providing information for predicting the risk of occurrence of a fracture or osteoporosis, including the step of measuring the expression level of a slit protein through an antibody binding reaction. The slit3 of the present invention increases bone formation in cells and animal models, decreases bone resorption, has a negative correlation with the incidence of osteoporosis, a composition for preventing or treating fractures or osteoporosis, and It can be usefully used as a biomarker for predicting the risk of occurrence of fractures or osteoporosis. [Selection] Figure 6 |